IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
Dulce M. Barrios, Gregory S. Phillips, Amaris Geisler, Sabrina Trelles, Alina Markova, Sarah Noor, Elizabeth Quigley, Helen Haliasos, Andrea P. Moy, Alison M. Schram, J. Bromberg, Samuel A. Funt, Martin H. Voss, Alexander Drilon, Matthew D. Hellmann, Elizabeth Comen, Saisindhu Narala, Anisha B. Patel, Megan Wetzel, Jae Yeon Jung, Donald Y.M. Leung, Mario E. Lacouture
Topics & Concepts
OmalizumabMedicineAdverse effectInternal medicineImmunoglobulin EDermatologyAnaphylaxisGastroenterologyAllergyImmunologyAntibodyCancer Immunotherapy and BiomarkersDermatology and Skin DiseasesUrticaria and Related Conditions